<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>374-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG1>
<DRUG2>
<CLASS name="BETA-BLOCKING AGENTS IN HEART FAILURE" code="C07AB-003" /></DRUG2>
<DESCRIPTION>Vasidilator effect and risk of hypotension, especially orthostatic (additive effect)</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>374-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG1>
<DRUG2>
<DRUG name="LITHIUM" rxcui="6448">
<ATC code="D11AX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of appearance of neuropsychic signs evocative of a neuroleptic malignant syndrome or of lithium poisoning</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>374-NEUROLEPTICS.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<CLASS name="NEUROLEPTICS" code="N05AA-003" /></DRUG1>
<DRUG2>
<DRUG name="ORLISTAT" rxcui="37925">
<ATC code="A08AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of therapeutic failure when there is concomitant treatment with orlistat</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
</INTERACTIONS>
